The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XVI.ar

Imaging: Pleural thickening w/wo rounded atelectasis

Publications

Pfitzenmeyer P, Foucher P, Dennewald G, Chevalon B, Debieuvre D, Bensa P, Piard F, Camus P

Pleuropulmonary changes induced by ergoline drugs.

The European respiratory journal 1996 May;9;1013-9 — 1996 May — 1013-9

Allen MB, Tosh G, Walters G, Muers MF

Pleural and pericardial fibrosis after ergotamine therapy.

Respiratory medicine 1994 Jan;88;67-9 — 1994 Jan — 67-9

Gefter WB, Epstein DM, Bonavita JA, Miller WT

Pleural thickening caused by Sansert and Ergotrate in the treatment of migraine.

AJR. American journal of roentgenology 1980 Aug;135;375-7 — 1980 Aug — 375-7